Descripción de la empresa
Q/C Technologies, Inc. operates as a clinical-stage pharmaceutical entity dedicated to the development and commercialization of therapeutic platforms based on diverse therapeutic targets, with a specific focus on Isomyosamine, a small molecule designed to regulate the immunometabolic system for treating autoimmune diseases. Despite its classification within the Technology sector and its specific industry designation as Computer Hardware, the company's operational activities are fundamentally rooted in pharmaceutical research and development, creating a distinct profile that blends technological infrastructure with life sciences objectives. The organization maintains a very small operational scale, employing only two individuals, which suggests a lean management structure typical of early-stage biotechnology ventures rather than large-scale hardware manufacturing operations. With a market capitalization of $27.02 million, the company's valuation reflects the high-risk, high-potential nature of clinical-stage assets, while the absence of reported annual revenue figures indicates that the business is currently in an investment phase where capital is being deployed for research rather than generated through commercial sales.
Salud financiera
The company reports a net income of $-11,559,973 over the trailing twelve-month period, while both revenue and EBITDA are listed as unavailable, creating a financial picture where significant losses are incurred without disclosed top-line sales to contextualize the burn rate. The substantial gap between the reported net income loss and the zero revenue implies that the company is operating at a stage where costs, likely driven by R&D expenditures and clinical trial expenses, vastly exceed any minimal or unrecorded commercial income, highlighting a cost structure entirely dependent on external capital inflows. Free cash flow stands at $-6,374,298, indicating a negative cash conversion that necessitates continuous fundraising to sustain operations and limits the company's financial flexibility for strategic acquisitions or unexpected market shifts. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, a figure that in the context of a clinical-stage company often results from accounting treatments where costs are capitalized or revenue recognition standards for early-stage products have not yet been met, effectively rendering traditional profitability analysis inapplicable. The company holds $10.00 million in cash reserves against a debt level that is not applicable, suggesting a conservative balance sheet approach where liquidity is prioritized over leverage, although the lack of a specific debt figure prevents a precise assessment of total liabilities. The current ratio is 1.71, which indicates that the company possesses 1.71 dollars of current assets for every dollar of current liabilities, providing a modest buffer for short-term liquidity needs despite the cash burn. Return on Equity is -40.6% and Return on Assets is -16.4%, revealing that management is currently destroying shareholder value and utilizing assets inefficiently in terms of generating positive returns, a common characteristic for firms in the development phase before a product reaches market approval.
Evaluación de valoración
Trailing P/E and forward P/E ratios are both unavailable due to the company's unprofitable status, a condition that precludes the use of earnings-based valuation multiples and implies that the market values the company based on potential future milestones rather than current earnings power. The price-to-book ratio is 0.72, indicating that the market capitalization is trading at 72% of its book value, which suggests the market places a discount on the company's assets, potentially reflecting the difficulty in valuing intangible clinical-stage assets or the high risk associated with the underlying technology. Alternative valuation metrics such as price-to-sales and EV/EBITDA are also unavailable, reinforcing the reliance on asset-based or venture-style valuation methods rather than traditional public market comparables. The 52-week high is recorded at $44.40 and the low at $2.50, representing an extreme volatility range where the current trading position fluctuates wildly, though without a specific current price provided, the exact percentage distance from the high or low cannot be calculated, yet the range itself underscores the speculative nature of the equity. The beta value is 2.23, which signifies that the stock price is expected to be 2.23 times as volatile as the broader market index, implying that price movements will be amplified significantly during periods of market stress or recovery.
Growth & Income
Revenue growth and earnings growth rates over the year-over-year period are both unavailable, preventing a direct comparison of the relative speed of earnings expansion versus top-line expansion or the identification of a specific growth trajectory. As a non-dividend payer, the company does not distribute a dividend yield or a payout ratio, meaning that all available earnings, including the reported losses, are effectively reinvested into the research and development pipeline rather than distributed to shareholders. The absence of a dividend program aligns with the company's lifecycle stage, where capital retention is essential to fund clinical trials and regulatory approvals rather than providing income to investors. The overall growth and income profile is characterized by a lack of historical financial data and an absence of income generation, positioning the equity as a pure growth play contingent on the successful progression of its clinical-stage assets rather than current profitability or cash flow generation.